Clinical Pharmacokinetics of Galantamine

Clinical Pharmacokinetics

Volumn 42, Issue 15, 2003, Pages 1383-1392

  Farlow, Martin R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DIGOXIN; DONEPEZIL; ERYTHROMYCIN; GALANTAMINE; KETOCONAZOLE; METRIFONATE; NEUROMUSCULAR BLOCKING AGENT; PAROXETINE; RIVASTIGMINE; WARFARIN;

ABDOMINAL PAIN; AGITATION; ALZHEIMER DISEASE; ANOREXIA; ASTHENIA; BACKACHE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FALLING; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; INJURY; INSOMNIA; MENTAL DISEASE; METABOLIC DISORDER; MULTIINFARCT DEMENTIA; NAUSEA; NONHUMAN; NUTRITIONAL DEFICIENCY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOMNOLENCE; TREMOR; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ALZHEIMER DISEASE; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; DRUG INTERACTIONS; FEMALE; GALANTAMINE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED;

EID: 0346099110     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200342150-00005     Document Type: Review

References (60)

1. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997; 278: 1363-71
2. Evans DA. Estimated prevalence of Alzheimer's disease in the United States. Milbank Q 1990; 68: 267-89
3. Pendlebury WW, Solomon PR. Alzheimer's disease. Clin Symp 1996; 48: 2-32
4. Bartus RT, Dean RL, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-14
5. Togashi H, Matsumoto M, Yoshioka M, et al. Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rats. Neurosci Lett 1994; 166: 117-20
6. Tanaka K, Ogawa N, Asanuma M, et al. Effects of the acetylcholinesterase inhibitor ENA-713 on ischemia-induced changes in acetylcholine and aromatic amine levels in the gerbil brain. Arch Int Pharmacodyn Ther 1993; 323: 85-96
7. Kimura S, Saito H, Minami M, et al. Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. Toxicology 2000; 153: 167-78
8. Szewczyk J, Lewin AH, Carroll FI. An improved synthesis of galanthamine. J Heterocycl Chem 1988; 25: 1809-11
9. Szewczyk J, Wilson JW, Lewin AH, et al. Facile synthesis of (±), (+)-, and (-)-galanthamine. J Heterocycl Chem 1995; 32: 195-9
10. Czollner L, Frantsits W, Küenburg B, et al. New kilogram-synthesis of the anti-Alzheimer drug (-)-galanthamine [abstract]. Tetrahedron Lett 1998; 39: 2087-8
11. Han S-Y, Mayer SC, Schweiger EJ, et al. Synthesis and biological activity of galanthamine derivatives as acetylcholinesterase (AChE) inhibitors. Bioorg Med Chem Lett 1991; 1: 579-80
12. Shieh W-C, Carlson JA. Asymmetric transformation of either enantiomer of narwedine via total spontaneous resolution process, a concise solution to the synthesis of (-)-galanthamine. J Org Chem 1994; 59: 5463-5
13. Bastida J, Viladomat F, Llabrés JM, et al. Narcissus nivalis: a new source of galanthamine. Planta Med 1990; 56: 123-4
14. Viladomat F, Bastida J, Codina C. Narcissus alkaloids, XVII: obesine, a novel alkaloid from Narcissus obesus. J Nat Prod 1992; 55: 804-6
15. Moraes-Cerdeira RM, Bastos JK, Burandt Jr CL, et al. Alkaloid content of different bulb parts of Narcissus cv. ice follies. Planta Med 1997; 63: 92-3
16. Baraka A, Harik S. Reversal of central anticholinergic syndrome by galanthamine. JAMA 1977; 238: 2293-4
17. De Angelis M, Walts LF. Comparison of galanthamine with neostigmine for reversal of d-tubocurarine neuromuscular blockade in man. Anesth Analg 1972; 51: 196-9
18. Cozanitis DA. Experiences with galanthamine hydrobromide as curare antagonist. Anaesthesist 1971; 20: 226-9
19. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54: 2261-8
20. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54: 2269-76
21. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 2000; 321: 1445-9
22. Rockwood K, Mintzer J, Truyen L, et al. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001; 71: 589-95
23. Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359: 1283-90
24. Woodruff-Pak DS, Vogel RW, Wenk GL. Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci U S A 2001; 98: 2089-94
25. Bickel U, Thomsen T, Weber W, et al. Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. Clin Pharmacol Ther 1991; 50: 420-8
26. Bores GM, Huger FP, Petko W, et al. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 1996; 277: 728-38
27. Thomsen T, Kaden B, Fischer JP, et al. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine. Eur J Clin Chem Clin Biochem 1991; 29: 487-92
28. Thomsen T, Kewitz H, Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci 1990; 46: 1553-8
29. Thomsen T, Bickel U, Fischer JP, et al. Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans. Eur J Clin Pharmacol 1990; 39: 603-5
30. Greenblatt HM, Kryger G, Lewis T, et al. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 Å resolution. FEBS Lett 1999; 463: 321-6
31. Sweeney JE, Puttfarcken PS, Coyle JT. Galanthamine, an acetylcholinesterase inhibitor: a time course of the effects on performance and neurochemical parameters in mice. Pharmacol Biochem Behav 1989; 34: 129-37
32. Thomsen T, Zendeh B, Fischer JP, et al. In vitro effects of various cholinesterase inhibitors on acetyl- and butyrylcholinesterase of healthy volunteers. Biochem Pharmacol 1991; 41: 139-41
33. Maelicke A, Albuquerque EX. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol 2000; 393: 165-70
34. Maelicke A, Samochocki M, Jostock R, et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 2001; 49: 279-88
35. Albuquerque EX, Alkondon M, Pereira EFR, et al. Properties of neuronal nicotine acetylchlorine receptors: pharmacological characterisation and modulation of synoptic function. J Pharmacol Exp Ther 1997; 280: 1117-36
36. Pereira EF, Alkondon M, Reinhardt S, et al. Physostigmine and galanthamine: probes for a novel binding site on the alpha 4 beta 2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells. J Pharmacol Exp Ther 1994; 270: 768-78
37. Schrattenholz A, Pereira EF, Roth U, et al. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 1996; 49: 1-6
38. Schröder B, Reinhardt S, Schrattenholz A, et al. Monoclonal antibodies FK1 and WF6 define two neighboring ligand binding sites on Torpedo acetylcholine receptor α-polypeptide. J Biol Chem 1994; 269: 10407-16
39. Storch A, Schrattenholz A, Cooper JC, et al. Physostigmine, galanthamine and codeine act as 'noncompetitive nicotinic receptor agonists' on clonal rat pheochromocytoma cells. Eur J Pharmacol 1995; 290: 207-19
40. Pereira EF, Reinhardt-Maelicke S, Schrattenholz A, et al. Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons. J Pharmacol Exp Ther 1993; 265: 1474-91
41. Samochocki M, Zerlin M, Jostock R, et al. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurol Scand Suppl 2000; 176: 68-73
42. Scott LJ, Goa KL. Galantamine: a review of its use in Alzheimer's disease. Drugs 2000; 60: 1095-122
43. Maelicke A, Albuquerque EX. New approach to drug therapy in Alzheimer's dementia. Drug Discov Today 1996; 1: 53-9
44. Santos MD, Alkondon M, Pereira EF, et al. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol 2002; 61: 1222-34
45. Barnes CA, Meltzer J, Houston F, et al. Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 2000; 99: 17-23
46. Albuquerque EX, Pereira EF, Mike A, et al. Neuronal nicotinic receptors in synaptic functions in humans and rats: physiological and clinical relevance. Behav Brain Res 2000; 113: 131-41
47. Alkondon M, Pereira EF, Eisenberg HM, et al. Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks. J Neurosci 2000; 20: 66-75
48. Maelicke A. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. Dement Geriatr Cogn Disord 2000; 11 Suppl. 1: 11-8
49. Levin ED, Simon BB. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl) 1998; 138: 217-30
50. Levin ED, Rezvani AH. Development of nicotinic drug therapy for cognitive disorders. Eur J Pharmacol 2000; 393: 141-6
51. Newhouse PA, Potter A, Corwin J, et al. Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology 1994; 10: 93-107
52. Gitelman DR, Prohovnik I. Muscarinic and nicotinic contributions to cognitive function and cortical blood flow. Neurobiol Aging 1992; 13: 313-8
53. Arthur D, Levin ED. Chronic inhibition of alpha4beta2 nicotinic receptors in the ventral hippocampus of rats: impacts on memory and nicotine response. Psychopharmacology (Berl) 2002; (16): 140-5
54. Mintzer JE, Yuan W, Kershaw P. Efficacy of galantamine in patients with Alzheimer's disease (AD) with previous exposure to cholinesterase inhibitors. Poster presented at American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico
55. Mihailova D, Yamboliev I, Zhivkova Z, et al. Pharmacokinetics of galanthamine hydrobromide after single subcutaneous and oral dosage in humans. Pharmacology 1989; 39: 50-8
56. Bachus R, Bickel U, Thomsen T, et al. The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6. Pharmacogenetics 1999; 9: 661-8
57. Reminyl® (galantamine hydrobromide) tablets [package insert]. Titusville (NJ): Janssen Pharmaceutica Products, LP, 2001
58. Jones RW, Cooper DM, Haworth J, et al. The effect of food on the absorption of galanthamine in healthy elderly volunteers [abstract]. Br J Clin Pharmacol 1996; 42: 671P
59. Wood DM, Ford JM, Wilcock GK, et al. Plasma protein binding of galanthamine; a potential agent for the treatment of Alzheimers' disease [abstract]. Eur J Clin Pharmacol 1997; 52 Suppl.: A161
60. Piotrovsky V, Van Peer A, Van Osselaer N, et al. Galantamine population pharmacokinetics in patients with Alzheimer's disease: modeling and simulations. J Clin Pharmacol. 2003; 43: 514-23